Drug Profile
Evinacumab - Regeneron Pharmaceuticals
Alternative Names: Evinacumab-dgnb; Evkeeza; REGN-1500Latest Information Update: 02 Feb 2024
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals; Sanofi
- Developer Regeneron Pharmaceuticals; Ultragenyx Pharmaceutical
- Class Antihyperlipidaemics; Monoclonal antibodies
- Mechanism of Action ANGPTL3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hyperlipoproteinaemia type II
- Phase II Hypertriglyceridaemia
Most Recent Events
- 18 Jan 2024 Registered for Hyperlipoproteinaemia type II in Japan (IV) - First global approval
- 04 Jan 2024 Launched for Hyperlipoproteinaemia type II (In adolescents, In children, In the elderly, In adults, Adjunctive treatment) in Germany, Canada, United Kingdom, Italy (IV)
- 04 Jan 2024 The UK's NICE issues final draft guidance recommending evinacumab for Hyperlipoproteinaemia type II